Journal of Comprehensive Pharmaceutical and Biomedical Sciences

RECENT ADVANCES IN AI-DRIVEN PHARMACEUTICAL CHEMISTRY AND DRUG DISCOVERY

Ravi Kumar Konda — 2026-05-15

Artificial intelligence (AI) has emerged as a transformative force in pharmaceutical chemistry and drug discovery by fundamentally reshaping how therapeutic molecules are designed, optimized, and evaluated. Traditional drug discovery processes are highly complex, costly, and time-consuming, often requiring more than a decade and billions of dollars to bring a single drug to market. Moreover, high attrition rates during clinical development further reduce efficiency in conventional pipelines. AI technologies, including machine learning (ML), deep learning (DL), neural networks, and natural language processing (NLP), have significantly improved the ability to analyze large-scale biological, chemical, and clinical datasets with high precision. These computational systems enable accurate prediction of molecular properties, biological activities, toxicity profiles, and pharmacokinetic behavior, thereby accelerating early-stage drug discovery.

In pharmaceutical chemistry, AI assists in molecular modeling, quantitative structure–activity relationship (QSAR) analysis, de novo drug design, and virtual screening of chemical libraries. These approaches reduce experimental workload and enhance the probability of identifying promising drug candidates. Additionally, AI-driven drug repurposing has gained attention for identifying new therapeutic uses of existing drugs, particularly during global health emergencies such as the COVID-19 pandemic. Integration of AI with systems biology and precision medicine has further enabled patient-specific therapeutic optimization. Despite these advancements, challenges such as limited high-quality datasets, algorithmic bias, lack of interpretability, and regulatory concerns persist. However, continuous progress in computational power, big data analytics, and cloud-based AI platforms is expected to overcome these barriers. This review highlights recent advances, applications, and future perspectives of AI-driven pharmaceutical chemistry and drug discovery in modern healthcare systems.

COLD CHAIN MANAGEMENT OF VACCINES AT PHARMACY LEVEL: BREAKING POINTS AND TECHNOLOGICAL SOLUTIONS

Narender Boggula — 2026-05-15

Cold chain management represents one of the most critical components of vaccine storage, transportation, and administration within modern healthcare systems. Vaccines are highly temperature-sensitive biological products that require strict maintenance of recommended storage conditions to preserve potency, immunogenicity, and clinical effectiveness. Even minor temperature excursions during transportation, storage, handling, or administration can compromise vaccine efficacy, increase wastage, and negatively impact public health immunization programs. At the pharmacy level, cold chain integrity becomes particularly important because pharmacists frequently serve as primary healthcare providers involved in vaccine procurement, storage, dispensing, counseling, and administration. Recent expansion of immunization services, including global COVID-19 vaccination campaigns and increasing utilization of biologics, has intensified the need for robust cold chain infrastructure within community and hospital pharmacies. Conventional cold chain systems face numerous challenges including power failures, improper refrigeration, inadequate staff training, transportation delays, poor inventory management, and limited temperature monitoring capabilities. Ultra-cold storage requirements for advanced vaccines such as messenger RNA formulations have further exposed vulnerabilities within existing pharmacy cold chain systems. Technological innovations including Internet of Things sensors, artificial intelligence, blockchain systems, smart refrigerators, automated temperature monitoring devices, cloud-based analytics, and predictive maintenance platforms are increasingly being integrated into vaccine cold chain management. These technologies enhance real-time monitoring, improve traceability, reduce human error, and strengthen vaccine quality assurance throughout the supply chain. Pharmacists play central roles in maintaining vaccine cold chain integrity through inventory control, storage management, patient education, adverse event monitoring, and implementation of regulatory guidelines. This manuscript reviews the principles, challenges, breaking points, pharmacist interventions, technological advancements, regulatory considerations, and future perspectives associated with vaccine cold chain management at the pharmacy level within contemporary healthcare systems.

NANOPARTICLE-BASED DRUG DELIVERY SYSTEMS IN CANCER PHARMACOLOGY: EMERGING INNOVATIONS AND THERAPEUTIC POTENTIAL

Sri Venkatesh Uriti — 2026-05-15

Cancer remains one of the leading causes of mortality worldwide despite major advances in pharmacological therapies. Conventional chemotherapy is frequently associated with poor selectivity, severe systemic toxicity, multidrug resistance, and limited bioavailability [1]. Recent innovations in pharmacology have increasingly focused on nanoparticle-based drug delivery systems (NDDS), which provide targeted and controlled drug release with improved therapeutic outcomes. Nanotechnology integrates pharmacology, molecular biology, and material science to enhance the effectiveness of anticancer drugs while minimizing adverse effects. Various nanocarriers including liposomes, polymeric nanoparticles, dendrimers, solid lipid nanoparticles, and metallic nanoparticles have shown considerable promise in overcoming the limitations of traditional chemotherapy. These systems improve drug solubility, prolong circulation time, enhance tumor targeting via the enhanced permeability and retention (EPR) effect, and reduce off-target toxicity. Emerging approaches such as ligand-mediated targeting, stimuli-responsive nanoparticles, and theranostic nanomedicine represent the future of precision oncology. This review discusses the recent advances, pharmacological mechanisms, clinical applications, advantages, limitations, and future perspectives of nanoparticle-based cancer therapeutics.

PHARMACOGNOSY IN THE ERA OF MODERN DRUG DISCOVERY: A COMPREHENSIVE REVIEW OF NATURAL PRODUCTS, INNOVATIONS, AND THERAPEUTIC POTENTIAL

Vamshi Sharathnath Kaveti — 2026-05-15

Pharmacognosy is the branch of pharmaceutical science that deals with the study of medicinal drugs derived from natural sources such as plants, microorganisms, marine organisms, and minerals. In recent decades, pharmacognosy has regained significant importance due to the rising demand for safe, effective, and affordable therapeutics. The global resurgence of interest in herbal medicine, bioactive natural compounds, and plant-based drug discovery is driven by limitations of synthetic drugs, including adverse effects, resistance, and high development costs. Advances in analytical chemistry, biotechnology, metabolomics, and molecular biology have transformed traditional pharmacognosy into a modern interdisciplinary science. This review highlights the evolution of pharmacognosy, classification of natural products, extraction and screening techniques, pharmacological importance of major phytoconstituents, and recent innovations such as nano-pharmacognosy, ethnopharmacology integration, and computational drug discovery. The article also discusses challenges, quality control issues, regulatory aspects, and future perspectives in natural product-based drug development.

PHARMACEUTICAL ANALYSIS AND QUALITY ASSURANCE IN DRUG DEVELOPMENT: EMERGING TECHNIQUES, REGULATORY FRAMEWORK, AND MODERN INNOVATIONS

Suchitra Duddagi — 2026-05-15

Pharmaceutical analysis and quality assurance (QA) are fundamental pillars of the pharmaceutical industry, ensuring the safety, efficacy, purity, and consistency of drug products. With increasing complexity in modern drug formulations, including biologics, nanomedicines, and combination therapies, advanced analytical and quality systems have become essential. Pharmaceutical analysis involves the identification, quantification, and purity assessment of drugs using classical and instrumental methods, while quality assurance ensures that all manufacturing processes comply with regulatory standards such as Good Manufacturing Practices (GMP). Recent innovations such as hyphenated techniques (LC-MS, GC-MS), quality by design (QbD), process analytical technology (PAT), and artificial intelligence-based quality monitoring have significantly improved drug development efficiency. This review discusses the principles of pharmaceutical analysis, modern analytical techniques, QA systems, validation protocols, regulatory guidelines, and emerging trends shaping the future of pharmaceutical quality systems.